FINGER ALISON CECILY 4

What Happened

• Alison Cecily Finger, a director of ADMA BIOLOGICS, INC. (ADMA), received two awards on Feb 9, 2026: 10,690 restricted stock units (RSUs) and 17,730 derivative units, both reported at $0 (total 28,420 units). No cash was paid — these are equity awards/compensation, not open-market purchases or sales.
• The 10,690 RSUs vest in two equal installments at the six- and 12-month anniversaries of the grant (fully vested on Feb 9, 2027), per the filing footnotes.

Key Details

• Transaction date: Feb 9, 2026; Form 4 filed Feb 11, 2026 (appears timely — Form 4 is generally due within two business days).
• Reported amounts/prices: 10,690 RSUs @ $0.00 (acquired); 17,730 derivative units @ $0.00 (acquired). Total reported units = 28,420.
• Shares/holdings after transaction (per footnote): the reporting person beneficially owned, as of the transaction date, 29,484 shares of common stock plus unvested RSUs (10,690 from this grant and 5,445 remaining from a prior grant), totaling 45,619 shares/RSU-equivalents.
• Vesting/footnotes: F1 describes the 10,690 RSUs vesting in two equal installments at 6 and 12 months; F2 enumerates current holdings (see above). No 10b5-1 sales, tax-withholding, or option exercises were reported in this filing.

Context

• RSUs and derivative awards represent the right to receive shares in the future subject to vesting and continued service; they are common compensation for executives and directors. These grants are not immediate purchases (which some investors view as a stronger bullish signal).
• Because this is an award/compensation event, it should be interpreted as part of governance/compensation activity rather than a direct insider market bet.